Lesofavumab

Lesofavumab (MHAB5553A) is a human IgG1κ anti-influenza B virus antibody[1].

Signaling Pathways >> Anti-infection >> Influenza Virus

Research Areas >> Infection

Influenza B virus[1]

Lesofavumab (MHAB5553A) 与血凝素 (HA) 残留酯酶结构域的一个保守表位结合，血凝素是 B 型流感病毒上的一种主要免疫显性表面糖蛋白，并在内体中阻断 HA 介导的膜融合[1]。 Lesofavumab (46B8) 能够中和所有 11 种与 >70 年人类感染相关的 IBV 菌株，IC50 值范围为 0.58-0.95 nM[2]。 Lesofavumab (46B8; 0-100 ng/mL) 在体外阻断膜融合并诱导抗体依赖性细胞毒性 (ADCC)[2]。

Lesofavumab (46B8; 15 mg/kg; i.v.; single dose) 能够保护小鼠免受突变型 B 型流感病毒的致命性[2]。 Animal Model: DBA/2 J mice, B/Wisconsin/1/2010, B/Brisbane/60/2008, B/Victoria/504/2000, B/Russia/1/1969 or B/Massachusetts/3/1966 infection model[2] Dosage: 15 mg/kg Administration: Intravenous administration, single dose, 24, 48 or 72 h post infection Result: Treatment at 24 and 48 h post infection resulted in 100% protection, with the only exception of mice infected with B/Russia/1/1969 that showed a 60% protection when treatment commenced at 48 h. Even when given at 72 h post infection, 48B8 was highly efficacious resulting in 100% protection against the B/Brisbane/60/2008, B/Victoria/504/2000 and B/Massachusetts/3/1966 strains, 75% protection against B/Wisconsin/1/2010 and 50% protection against B/Russia/1/1969.

[1]. Rao GK, et al. In Vivo Assessment of Antibody-Dependent Enhancement of Influenza B Infection. Toxicol Sci. 2019 Jun 1;169(2):409-421.  

[2]. Chai N, et al. A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action. Nat Commun. 2017 Jan 19;8:14234.